Ignite Creation Date:
2024-05-06 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05142475
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2021-11-24
Brief Title:
Study on TIL for the Treatment of Advanced Breast Cancer
Sponsor:
Shanghai Juncell Therapeutics
Organization:
Shanghai Juncell Therapeutics
Study Overview
Official Title:
A Clinical Study on TIL for the Treatment of Advanced Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte TIL therapy GC 101 TIL in patients with advanced breast cancer Autologous TILs are expanded from tumor resections or biopsies and infused iv into the patient after NMA lymphodepletion treatment with hydroxychloroquine600mgsingle-dose and cyclophosphamide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None